Study design:
• Double blinded, non-inferiority, prospective parallel-group, intend to treat trial.
Study design:
- Experiment duration: 30 weeks
- 9 visits (days 0, 14, 42, 70, 98, 126, 154, 182, 210)
- Health Assessment Questionnaire (HAQ) evaluation
- Disease Activity Score (DAS28) evaluation
- Clinical Disease Activity Index (CDAI) evaluation
- American College of Rheumatology criteria (ACR) evaluation
- Visual Activity Schedule(VAS) evaluation
- Adverse events evaluation
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01394913?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
